Kite Reports Fourth Quarter and Full Year 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- US stock futures rise on tech rebound before Nvidia, inflation tests
- Oil hits one-week low as investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Kite Pharma (KITE) Resume Trading; Shares up 18%
February 28, 2017 10:26 AM ESTKite Pharma (NASDAQ: KITE) resumes trading and is up 18.8% following earlier positive data.
... MoreKite Pharma (KITE) to resume trading at 10:25AM ET
February 28, 2017 10:10 AM ESTKite Pharma (NASDAQ: KITE) to resume trading at 10:25AM ET following earlier data
... MoreKite Pharma (KITE) Tops Q4 EPS by 44c
February 28, 2017 8:02 AM ESTKite Pharma (NASDAQ: KITE) reported Q4 EPS of ($1.31), $0.44 better than the analyst estimate of ($1.75). Revenue for the quarter came in at $4.9 million versus the consensus estimate of $5.6 million.
2017 Financial Guidance
Kite expects full year 2017 net cash burn to be between $325 million and $340 million, which... More